Jeff Lewis

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC

Xiuning Le, Sonam Puri, Marcelo V. Negrão et al. · Clinical Cancer Research · 2018 · 386 citations

Medicine, Oncology, Pharmacology +17

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong, Marcelo V. Negrão, Seyedeh Dibaj et al. · Journal of Thoracic Oncology · 2020 · 192 citations · Full text

Medicine, Immunology, Oncology +17

<i>STK11</i> /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition

Piyada Sitthideatphaiboon, Ana Galán‐Cobo, Marcelo V. Negrão et al. · Clinical Cancer Research · 2020 · 115 citations · Full text

Medicine, Molecular Genetics, Oncology +17

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Marcelo V. Negrão, Vincent K. Lam, Alexandre Reuben et al. · Journal of Thoracic Oncology · 2019 · 112 citations · Full text

Life Sciences, Immunology, Oncology +17

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Maliazurina B. Saad, Lingzhi Hong, Muhammad Aminu et al. · The Lancet Digital Health · 2023 · 109 citations · Full text

Medicine, Cancer Biology, Oncology +17